Drug Approval | March 03, 2022
Lupin receives USFDA approval for topical solution
The product will be manufactured at Lupin’s facility in Pithampur, India
The product will be manufactured at Lupin’s facility in Pithampur, India
Company expects strong organic growth in sales, EBITDA in 2022
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
This has further strengthened its manufacturing presence in the United States of America
High level of vaccine efficacy maintained over a 6-month period of surveillance
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Subscribe To Our Newsletter & Stay Updated
